Trial Profile
A Phase III Multicenter, Double-blind, Placebo-controlled, Study Evaluating the Safety, and Efficacy of STR001 Treatment in Adults With Sudden Sensorineural Hearing Loss
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2020
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Pioglitazone (Primary)
- Indications Hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE
- Sponsors Strekin
- 24 Mar 2020 Status changed from active, no longer recruiting to completed.
- 11 Sep 2019 Status changed from recruiting to active, no longer recruiting, according to a Strekin media release.
- 02 Sep 2019 According to a Strekin media release, the top-line results for this study are anticipated in early 2020.